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Abstract  
Arrhythmogenic right ventricular cardiomyopathy/ 
dysplasia (ARVC/D), mostly affecting young/middle-aged 
individuals, poses a significant risk of malignant 
ventricular arrhythmias (VAs) and subsequent sudden 
cardiac death (SCD). Antiarrhythmic agents (AAA) 
provide insufficient arrhythmia suppression and 
prevention and can be proarrhythmic. Thus, the 
implantable cardioverter-defibrillator (ICD) is considered 
the first-line treatment, especially in patients with 
secondary prevention indication. Nevertheless, catheter 
ablation is an additional therapy to the ICD which has 
proved its efficacy in primary and secondary prevention of 
fatal arrhythmias and sudden cardiac death. The 
superiority of the combined endo- and epicardial VT 
ablation in this population is clear since ARVC/D substrate 
has been shown to be mostly epicardial. Due to progressive 
nature of ARVC/D, ablation seems to be a useful tool for 
the patients who experience recurrent VT episodes or 
electrical storms.  
Key Words: sudden cardiac death; arrhythmogenic right 
ventricular cardiomyopathy/dysplasia; ventricular 
tachycardia/fibrillation; implantable cardioverter defibrillator; 
catheter ablation/mapping  
Abbreviations 
AAA = antiarrhythmic agents; ARVC/D = arrhythmogenic right 
ventricular cardiomyopathy / dysplasia; EAM = electro-
anatomical mapping; EPS = electrophysiology study; ICD = 
implantable cardioverter defibrillator; LV = left ventric-le(-
ular); RFA = radiofrequency catheter ablation; RV = right 
ventric-le(-ular); SCD = sudden cardiac death; VAs = ventricular 
arrhythmias; VF = ventricular fibrillation; VT = ventricular 
tachycardia  
Introduction 
Arrhythmogenic right ventricular cardiomyopathy/ 
dysplasia (ARVC/D) poses a significant risk of malignant 
ventricular arrhythmias (VAs) and subsequent sudden 
cardiac death (SCD).1 On top of the fact that young/ 
middle-aged individuals are mostly affected, imperative 
issues emerge regarding primary and secondary prevention 
of catastrophic ventricular arrhythmogenesis.1 
Antiarrhythmic agents (AAA) provide insufficient 
arrhythmia suppression and prevention and can be 
proarrhythmic.2 In this context, implantable cardioverters-
defibrillators (ICDs) are considered the first-line 
treatment, especially in patients with an indication for 
secondary prevention of SCD.3 However, a substantial 
amount of discrepancy remains as to which patients 
without documented VAs are optimal candidates for ICD 
implantation, based on arrhythmic risk stratification 
schemes. Prospective studies in patients with implanted 
ICDs according to the arrhythmic risk factors let somebody 
see that only a minority of them receive appropriate ICD 
intervention, while significant proportions present with 
inappropriate ICD interventions and/or device-related 
complications.4  
In all cases, what ICDs are incapable of is prevention 
of arrhythmias occurrence and, of more importance, 
modification or elimination of the arrhythmogenic 
substrate. Radiofrequency catheter ablation (RFA) 
effectively modifies and/or eliminates abnormal 
arrhythmogenic substrate. In post-infarction patients with 
mainly subendocardial scars and slow conduction areas, 
RFA is an established therapy for malignant ventricular 
arrhythmias.5 Regarding ARVC/D, though, the abnormal 
substrate appears not to be confined to the 
subendocardium. In fact, recent research work has 
demonstrated the presence of scarring, creating re-entry 
circuits due to slow conduction and unidirectional block 
promoting thus arrhythmogenesis in the epicardium.6 
State-of-the-art ablation procedures include epicardial 
electroanatomical mapping (EAM) and ablation, not only 
after failure of endocardial ablation, but even as first-line 
approach.7 The combined use of endocardial and epicardial 
ablation has given more than encouraging results in 
patients presenting with VAs and has raised significantly 
rates of arrhythmia-free survival.7,8  
Electroanatomic and Electrophysiologic Substrate 
ARVC/D is a genetically determined cardiomyopathy 
which typically affects the right ventricle (RV); 
involvement of the left ventricle (LV) is now commonly 
recognized, especially in the late stages of the disease, 
while recent data suggests that it may in fact precede the 
onset of significant RV dysfunction.9-12 It primarily results 
from defective desmosomal proteins with the subsequent 
myocardial degeneration and death causing replacement of 
right and/or ventricular myocardium by fibrofatty 
tissue.9,13,14 Along with RV enlargement and dysfunction, 
RV aneurysms are typical of ARVC/D and are detected in 
the so-called "triangle of dysplasia", i.e., RV outflow tract, 
apex, and outflow tract.15 Sites of left ventricle (LV) 
involvement, demonstrated by late enhancement cardiac 
magnetic resonance (LECMR), include more often the 
inferolateral wall, inferior wall-septal junction, inferior 
wall and septum.12 Through functional myocardial tissue 
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degeneration and replacement, the two principal 
prerequisites for reentry are met. The intercellular coupling 
is deranged leading to slower impulse conduction and, 
secondly, areas of anatomic and/or functional 
unidirectional block are created.  
High-density electroanatomic mapping (EAM) has 
been used to characterize the electrical correlates of 
arrhythmogenic substrate in ARVC/D. Bipolar RV 
endocardium signals are considered normal if they display 
up to 3 deflections from baseline, with amplitude of more 
than 1.5 mV, while dense scar is demonstrated by 
amplitudes less than 0.5 mV.16,17 Regarding the 
epicardium, an amplitude in the bipolar setting of more 
than 1.0 mV is considered normal, which corresponds to 
95% of the signals recorded at a distance at least 1 cm from 
the defined large vessel coronary vasculature18. In patients 
with minimal or moderate endocardial disease 
involvement, the extent of epicardial scar can also be 
reliably evidenced with application of endocardial 
unipolar mapping, using a cutoff of <5.5 mV for normal 
endocardial unipolar voltage.19 The areas of endocardial 
electroanatomic scar, as defined by studies conducted to 
seek endocardial ventricular tachycardia (VT) ablation 
efficacy, extend from the tricuspid or pulmonary valve to 
the RV free wall, while the RV apex seems to be 
excluded.20,21 High-density EAM in the epicardium has 
revealed that low-voltage epicardial areas correspond well 
to endocardial anatomical ones but  extend further over the 
surface of the RV.7,22 In ARVC/D the RV epicardium 
activation is delayed and  independent of the underlying 
endocardium activation. In particular, 
compartmentalization of the epicardium from the 
endocardium and VT circuits defined only to the 
epicardium are created, explaining the low rates of success 
and high rates of VT recurrence when an endocardial-only 
ablative strategy is applied.6 Of importance, the existence 
of scarring and low voltage areas does not dogmatically 
predict arrhythmic events. As Santangeli et al23 report, in 
primary prevention patients prospectively followed after 
ICD implantation, fragmented and late activation 
potentials recorded within the scar and not RV 
electroanatomic scar itself, were linked with subsequent 
malignant arrhythmogenesis.  
Risk Stratification and Management 
The majority of affected individuals develop symptoms 
during the second to fourth decade of life. The latter, 
especially during the early “concealed” stage of the 
disease, where gross changes in the cardiac muscle 
architecture are difficult or impossible to define, include 
mainly malignant ventricular arrhythmias, syncope and in 
some cases SCD.10 Survivors of cardiac arrest present 
mainly with sustained ventricular tachycardia (VT) or 
ventricular fibrillation (VF), receive an ICD in the context 
of secondary prevention and have rates of VT/VF 
incidence of up to 70% during follow up. 24,25  
The subgroup of patients without documented VAs is 
typically stratified according to arrhythmic risk factors. 
Such factors include induction of VT during an 
electrophysiology study (EPS), detection of non-sustained 
VT on noninvasive monitoring, male gender, severe RV 
dilation, extensive RV involvement, young age at 
presentation (less than 5 years), LV involvement, prior 
cardiac arrest, unexplained syncope and genotypes of 
ARVD/C associated with a high risk for SCD.3 The John 
Hopkins registry reported 48% appropriate ICD 
interventions during follow-up. Inducibility at EPS, non-
sustained VT and high burden of ventricular ectopy were 
independent strong predictors of appropriate ICD 
therapy.26 On the other hand, Corrado et al report a lower, 
albeit significant, percentage of 24%. They define syncope 
as an important predictor of life-saving ICD intervention, 
while programmed ventricular stimulation seems to have a 
low predictive accuracy for appropriate ICD intervention.4  
Catheter Ablation  
A significant proportion of appropriate ICD therapies is 
delivered due to episodes of  electrical storm.27,28 The 
aforementioned data sufficiently highlight the urge for 
therapies that move one step forward in the field of 
arrhythmogenic substrate modification/elimination rather 
than malignant VAs termination. General 
recommendations regarding catheter ablation indications 
in patients with structural heart disease are summarized in 
Table 1. 29 
 
Table1. Indications for catheter ablation of ventricular 
tachycardia associated with structural heart disease29 
 
1 
Recurrent symptomatic sustained monomorphic VT 
(SMVT), including VT terminated by an ICD despite 
AAA or when AAA are not tolerated or not desired 
2 Control of incessant SMVT or VT storm that is not due to a transient reversible cause 
3 
Recurrent sustained polymorphic VT and VF refractory 
to AAA when there is suspected trigger that can be 
targeted for ablation 
AAA = antiarrhythmic agents; ICD = implantable cardioverter 
defibrillator; VF = ventricular fibrillation; VT = ventricular 
tachycardia  
In patients with ischemic cardiomyopathy (ICM), RFA 
has been shown to be more efficacious compared to 
individuals with non-ischemic cardiomyopathies. In the 
field of ARVC/D the results from the studies carried out in 
patients with VTs are controversial. Although there are no 
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large clinical trials in this population, the results are not 
encouraging regarding RFA. As in ICM, two end-points 
have been proposed indicating acute success, either non-
inducibility of the clinical VT or of any inducible VTs. The 
first clinical studies during late 90’s enrolled only a few 
patients and the procedures were carried out 
conventionally, typically with pace- and entrainment 
mapping techniques, without using EAM systems. One of 
them was conducted by Harrada et al, who enrolled 7 
patients using entrainment endocardial mapping to identify 
the reentrant circuit. They demonstrated that RFA was 
most successful at narrow isthmuses of the re-entry 
circuits, proving that in this population re-entry 
predominates as VT generating mechanism.30 Although 
nowadays RFA is the commonly used technique, in the 
early 1990s direct current (DC) fulguration was also 
widely used. According to Fontaine et al, who compared 
the efficacy of these two techniques in patients with 
ARVC/D, the effectiveness/efficacy of RFA alone was 
about 40%, while DC fulguration was successful after 
RFA failure. In these 50 patients, the success rate during 
the follow up was 81% for DC ablation and 93% for 
combined DC and RFA.31  
Moreover, in the past years a non-contact mapping 
technique with a balloon catheter was introduced in the 
clinical practice of VT ablation. This technique using the 
far-field unipolar electrograms obtained from the 
endocardium allows the creation of an activation map, 
although sometimes it is not possible to detect the low 
voltage electrograms. In patients with ARVC/D, results 
seem to be promising, since in a group of 32 subjects acute 
success was achieved in 84.4% of them and at the end of 
follow up 81.3% were free of VT.32  
Table 2 summarizes the results from the most important 
published clinical trials for VT ablation in patients with 
ARVC/D. Due to different ablation techniques, endpoints 
used and the overall post ablation management of the 
patients, regarding the use of AAA, ICDs and follow up 
duration, there is an obvious variability among these 
results. Most of the studies published after 2000 included 
patients with implanted ICDs, either before inclusion or 
during the study, since its effectiveness is undeniable. A 
large observational study showed that about half of the 
patients with ARVC/D had at least one episode of 
ventricular tachyarrhythmia that required ICD therapy 
over a mean follow-up period of 3.3 years, and 24% 
experienced potentially fatal arrhythmias as ventricular 
fibrillation or flutter, suggesting thus the beneficial effect 
of the ICDs.33 Ablation in these patients seems to reduce 
the number of VA episodes especially when it is performed 
both endocardially and epicardially. Recently published 
data showed that, in a population of 49 patients, 52.2% 
were free of VAs or ICD therapy during a 3-year follow up 
after endocardial ablation compared to 84.6% after 
combined endo- and epi-cardial ablation (P=0.029). 
Moreover, patients with frequent premature ventricular 
contractions after ablation were more likely to have VA 
recurrence or ICD therapy (P<0.001).7   
Table 2. Clinical Outcomes of Ventricular Tachycardia Ablation in Patients with ARVC/D. 
Study Patients characteristics 
No of 
procedures
/episodes 
Ablation 
approach 
Acute success 
rate 
Compli-
cations Recurrence rates Additional comments 
Harada et al 
30 
7 pts, FU 19 ± 
7 months 
8VTs Entrainment 
endocardial 
mapping & 
RF 
17% of exit sites, 
67% of proximal 
sites & 8% of 
outer loop sites 
 1 pt (chemical 
ablation RCA) 
RFA is most 
successful at narrow 
isthmuses of the 
reentry circuits 
Fontaine G 
et al31  
50 pts, 48 ± 15 
yrs old during 
16 yrs, mean 
FU 5.8 yrs 
 Endocardial 
mapping, 
DC (27 pts) 
& RFA 
Clinical success 
after 3 sessions 
RFA+DC: ~90%  
Death rate 
3% per year, 
3 pts had 
tamponade 
 RFA plus DC ablation 
effective after failed 
RFA in the same 
session 
Marchlinski 
et al37  
21 pts mapping 
/19 pts abl, all 
had ICD, FU 
27±22 months 
66 VTs 21 pts endo 
(RV, 18 pts 
LV) 
14/19 (74%) acute 
success 
none 17/19 pts no VT, 2 
pts (≤1 episode/3 
months FU) 
>1 Ablation required 
in 13 pts 
Verma et al 
38 
22 pts, aged 
41±15 y, 18 pts 
ICD, median 
FU 37 months 
3±2 VT/pt Endocardial 
with 
CARTO 
18/22 pts 1 pt had 
cardiac 
tamponade 
8 pts, but with 
slower VTs 
Scar areas: TA, 
proximal RVOT, 
anterior/inferior-apical 
walls 
Satomi et al 
20 
17 pts, 26 ± 15 
months  
13 stable 
VTs, 13 
unstable 
VTs 
Endocardial 
with 
CARTO 
13/17 pts were 
free of symptoms, 
2pts received ICD 
No  2 pts had VT 
recurrence  
Diastolic or 
fragmented  potentials 
were recorded along 
TA or RVOT  
Dalal et al 
40 
24 pts, 36±9 
yrs, 19 pts ICD, 
FU 32±36 
months 
48 RFA 10 with 3D 
mapping/  
38 con-
ventional 
22/48 successful 
procedures  
1 procedure 
related 
death 
8 ±10 months 
recurrence time 
after abl., 40/48 
no difference in VT 
recurrence-free 
survival between 
patients with complete 
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procedures (85%), 4 
pts el. storm  
or partial procedural 
success and failure 
Yao et al 32 32 pts, 37±13 
yrs, 2 pts had 
ICD, 28.6 ±16 
months FU 
67 induced 
VTs, CL: 
210±32 ms 
Non contact 
mapping, 
Ensite  
27/32 pts None 81.3% free of VTs 
without AAA 
Non contact mapping 
is useful for fast VTs 
ablation  
Reithmann 
et al 40 
11 pts, 53±13 
y,  6 pts had 
ICD implanted 
at end of FU, 
27±17 months  
18 VTs,  Entrainment 
mapping 
with 
CARTO 
10 VTs (9 pts) 
successful ablated  
No 
complicatio
ns 
6/11 pts had 
recurrence (FU 
every 3 months  
isolated diastolic 
potentials in SR were 
associated with 
successful RFA at 
reentry circuit isthmus 
sites 
Garcia et al 
35 
13 pts, 43±15 
yrs, FU 18±13 
months, 
Recurrent 
VTs after 
endocardial 
ablation 
(mean 2 
abl.) 
Endo- & 
epicardial 
with 
CARTO 
11/13 pts (85%) 
non inducible 
monomorphic VT,  
12 /13 pts (92%)  
elimination of all 
VTs 
No compli-
cations 
10/13 pts (77%) free 
of sustained VT 
ARVC/D is associated 
with a more extensive 
epicardial area of 
electrogram 
abnormalities & 
frequently basal RV 
wall thickening 
Pokushalov 
et al36 
17 pediatric 
pts, 14 ±4 y, 
FU 26±15 mos, 
recurrent VTs 
failure AAD 
endo- prior 
ablation, 5 pts 
had ICD 
 Endo- & 
epicardial  
16/17 pts (94.1%)  
had non inducible 
VT 
4 pts had 
pericardial 
effusion 
12 pts (70.6%) free 
of arrhythmia 
Failure of endocardial 
RFA due to: RV 
periannular thickness, 
45% of pts had 
mismatch of endo-
&epi- findings, in 
fibrotic areas endo-
cardial ablation was 
ineffective 
Komura et 
al 41 
35 pts (ICD & 
RFA), 5 pts 
ICD+RFA, 14 
pts RFA, 45.6± 
15.6 y, FU 
54.5±48.2 mos 
    19/10 pts RFA 
(52.6%) 14.0±20.1 
mos,18/30 pts 
received ICD, 
recurrence 6/18 pts 
(33%) at 5.3±4 mos  
ICD reduced 
recurrence of VTs 
compared to RFA  
Nair et al 42 15 pts, 44±15 
y, 5 pts had 
ICD, FU 25±16 
months 
26 
inducible 
VTs 
Only endo-
cardial VTs, 
(Ensite 
system) 
23/26 VTs were 
successfully 
ablated  
No 
complicatio
ns 
2 pts had recurrence 
of non-clinical VT  
AAA discontinued 
after 6 months 
Bai et al 7 49 pts with 
ICD, FU 1224± 
310 d endo-, 
1175±112 days 
endo-epicardial 
2 VTs/pt 
(median) 
23 endo-, 26 
endo-/epi-
cardial with 
CARTO 
End point: non-
inducible suMVT 
No major 52.2% group 1 
and 84.6%  in group 
2 free of VA, 
endo-epicardial RFA 
results in discontinu-
ation of AAA; PVCs 
after RFA was asso-
ciated with recurrence  
Della Bella 
et al43 
13 pts, 
17.3±18.2 
months 
 Endo-
/epicardial 
9(69.2%) non 
inducible VT 
1 pt minor 
complicatio
n 
4 pts (3 with the 
same morphology) 
 
Philips et al 
2012 8 
87 pts,  
 38±13 years, 
95% had ICD, 
mean FU  
 88.3±66 
months 
175 
procedures, 
average 2.3 
procedures/
pt 
Endo- & 
epicardial 
47% acute / 38% 
partial success, & 
procedural failure 
in 15% of 160 
procedures, 53% 
of pts had repeat 
ablations 
2 major 
associated 
with 
epicardial 
19% freedom from 
VT after a single 
endocardial RFA 
compared to 45% 
after a single epi-
cardial RFA at 5 y 
(P=0.021) 
VT-free survival was 
significantly longer 
after epicardial RFA 
than after endocardial  
(P=0.003) 
Haqqani et 
al 6 
18 pts, 43±15 
years compared 
to 6 pts with 
normal heart, 
15/18 pts had 
ICDs 
28 VTs 
were 
induced, 9 
were 
mappable  
Endo- & 
epicardial 
with  
CARTO 
20/22 VTs after 
epicardial ablation 
were non-
inducible  
  Epicardial RV 
activation pattern is 
often independent of 
endocardial activation 
suggesting that the 
fibrosis may 
compartmentalize the 
endocardium from the 
epicardium  
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Although the acute success rate after VT ablation seems 
to be satisfactory in patients using an endocardium-
confined approach, late recurrence remains a principal 
drawback. Recent advances in EAM and catheter ablation 
technology have contributed to the better understanding of 
the VT substrate in ARVC/D. Electroanatomical mapping 
data were compared between patients with ARVC/D and 
patients without structural heart disease who both 
underwent endocardial and epicardial mapping (Fig. 1). 
The identified scar area was larger in the epicardium 
compared to the endocardium (P=0.04). Additionally, 
ARVC/D patients had longer epicardial and endocardial 
activation times compared to controls. Specifically, in 
these patients a more than four-fold greater delay between 
the last recorded endocardial activation and the latest 
epicardial right ventricular sites was demonstrated, 
simultaneously with the presence of late epicardial isolated 
potentials. On the contrary, the control patients had the 
latest epicardial activation within 20 ms after the latest RV 
endocardial activation.6 The same activation template 
became clear after direct surgical mapping in 4 patients 
with ARVC/D, which showed the earliest activation points 
in the epicardium.34 Garcia et al performed epicardial 
ablation in 12 out of 13 patients with failed endocardial 
ablation and after a mean follow up of 18±13 months, 77% 
of the patients were free of sustained VT. The authors 
noted that the epicardial VT origin site was in proximity to 
the tricuspid annulus at the acute angle of the RV and this 
epicardial successful ablation region was in some of the 
patients >1 cm away from the previous failed endocardial 
ablation site.35 More recently, Bai et al7 compared the long-
term results by using endocardium-confined ablation 
versus endo-epicardial substrate-based ablation in patients 
with ARVC/D, reporting a rate of freedom from any VT of 
52.2% and 84.6%, respectively. The existence of more 
than 10 premature ventricular complexes per minute was 
associated with more high percentage of VT recurrence. 
Added to the latter, newer data confirm the superiority of 
epicardial ablation in this population. In 87 patients from 
80 different centers, those who underwent epicardial 
ablation were free from VT recurrence by 64% and 45% at 
1 and 5 years of follow up, respectively, which was 
significantly larger compared to endocardial RFA 
(P=0.021).8 The incidence of major complications during 
the pericardial procedures was about 7.7%, similar to those 
reported in the literature about all VT categories epicardial 
ablation. Epicardial ablation seems also to be efficient in 
pediatric patients with ARVC. Pokushalov et al36 showed 
that in 17 pediatric patients with recurrent VTs due to 
failed prior endocardial ablation or AAA inefficacy, 
epicardial VT ablation resulted to non-inducibility of the 
VT in most of them (16 of 17 pts). After a follow-up period 
of 26±15 months without receiving AAA, 70.6% of them 
were free of arrhythmia episodes.   
Conclusion 
In patients with ARVC/D, catheter ablation is an 
additional therapy to the ICD which has proved its efficacy 
in primary and secondary prevention of fatal arrhythmias 
and sudden cardiac death. The superiority of the combined 
endo- and epicardial VT ablation in this population is clear, 
since the ARVC/D substrate has been shown to be mostly 
epicardial. Due to progressive nature of ARVC/D, ablation 
seems to be a useful tool for the patients who experience 
recurrent VT episodes or electrical storms. Using the new 
three-dimensional (3D) EAM mapping systems we are 
able to modify the arrhythmogenic endocardial and/or 
epicardial substrate and to abolish the re-entrant circuits 
which are responsible for the genesis of these macroreentry 
or focal tachycardias. Larger well organized multicenter 
trials are required to investigate the long-term effect 
favorable or not of the ablation therapy in these patients 
using the current endocardial and epicardial approach.    
  
Figure 1. Endocardial (ENDO) and epicardial (EPI) voltage 
maps with the CARTO-3 system of a patient submitted for 
ventricular tachycardia ablation and diagnosis of ARVD in right 
lateral view. A low-voltage area is present in the epicardial 
surface. The epicardial scar is wider than the endocardial. 
Normal myocardium (>1.5 mV) is coded in purple, scar (<0.5 
mV) is coded in red. Red dots: radiofrequency applications.  
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